88 studies found for:    Open Studies | "Nasopharyngeal Neoplasms"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Intensity Modulated Radiation Therapy for Head and Neck Cancer
Condition: Nasopharyngeal Neoplasms
Interventions: Procedure: intensity modulated radiation therapy;   Drug: cisplatinium and fluorouracil - standard treatment
2 Not yet recruiting Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Neoplasms;   Blood Cell Count;   Neoplasm Staging;   Prognosis
Intervention:
3 Unknown  Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: Oxaliplatin
4 Not yet recruiting Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
Condition: Nasopharyngeal Neoplasms
Interventions: Procedure: Conventional Radiotherapy;   Procedure: Accelerated Radiotherapy;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Capecitabine
5 Recruiting Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: gemcitabine and cisplatin;   Drug: 5-Fluorouracil and cisplatin
6 Recruiting Environmental and Genetic Determinants of NPC
Conditions: Nasopharyngeal Neoplasms;   Herpesvirus 4, Human
Intervention:
7 Recruiting A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
Conditions: Nasopharyngeal Neoplasms;   Salivary Gland Diseases;   Bone Marrow Diseases;   Mucositis
Interventions: Drug: Amifostine every-other-day regimen;   Drug: Amifostine everyday regimen
8 Not yet recruiting The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma
Condition: Effects of Chemotherapy
Interventions: Drug: Concurrent chemotherapy with cisplatin;   Radiation: Intensity modulated radiotherapy
9 Recruiting Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis
10 Unknown  A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
11 Recruiting Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
Condition: Recurrent Nasopharynx Carcinoma
Interventions: Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Ifosfamide;   Procedure: Autologous Stem Cell Transplantation
12 Recruiting TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: TLR8 agonist VTX-2337;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
13 Unknown  Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: FOSCAN
14 Recruiting Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial
Condition: Local Advanced High Risk Nasopharyngeal Carcinoma
Interventions: Drug: IMRT combine with cisplatin concurrent chemotherapy;   Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
15 Recruiting Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
16 Recruiting A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: nedaplatin and docetaxel;   Drug: cisplatin and docetaxel
17 Recruiting Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy
Conditions: Nasopharyngeal Carcinoma;   Radiotherapy
Interventions: Behavioral: Traditional rehabilitation (TR);   Behavioral: Transcutaneous electrical stimulation (ES)
18 Recruiting Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)
Condition: Nasopharyngeal Carcinoma
Intervention:
19 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Conditions: Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Tongue Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: fluorouracil;   Drug: hydroxyurea;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis
20 Not yet recruiting The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: One cycle TPF induction chemotherapy for NPC;   Drug: Three cycles TPF induction chemotherapy for NPC

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years